Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Change in Account Payables (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Change in Account Payables for 4 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 352.2% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 206.33% year-over-year, with the annual reading at $1.6 million for FY2025, 206.33% up from the prior year.
  • Change in Account Payables for Q4 2025 was $2.2 million at Century Therapeutics, up from -$591000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $4.0 million in Q3 2023, with the low at -$3.0 million in Q1 2023.
  • Average Change in Account Payables over 4 years is -$441000.0, with a median of -$552500.0 recorded in 2023.
  • The sharpest move saw Change in Account Payables surged 465.72% in 2023, then plummeted 265.37% in 2024.
  • Over 4 years, Change in Account Payables stood at -$1.6 million in 2022, then plummeted by 76.79% to -$2.9 million in 2023, then soared by 116.52% to $477000.0 in 2024, then surged by 352.2% to $2.2 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $2.2 million, -$591000.0, and -$365000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.